Diffucaps® Customized Release Technology

Adare has recently launched a new patient centric dosage solution, the Parvulet TM Technology. The Parvulet TM Technology enables a solid powder or tablet to convert to a semi-solid in the presence of water within thirty seconds. The final dosage is easily administered, as a soft food like texture, ide...

AdvaTab® Orally Disintegrating Tablets (ODTs) incorporates coated or uncoated drug particles that are uniformly dispersed in a low-moisture, rapidly disintegrating matrix. Each ODT is formulated to achieve an acceptable taste and desired release profile. AdvaTab® technology is ideal for patients who ha...

Microcaps® Taste Masking Technology achieves uniform and efficient coating of drug particles by a combination of coacervation (phase separation) and spray coating to build polymeric membranes of varying porosity and thickness. The completely encapsulated particle allows for a pleasant mouthfeel wi...

MMTS TM Multi Mini Tablet System Customized Release Technology combines the simplicity of a tablet formulation with the flexibility of multiparticulate dosage forms with high drug-loading capability. Adare has developed Ultra Microtablets—a smaller standard of tablets targeting diameters in the range o...

In Philadelphia in May on site at CPHI North America we were able to meet with some of our speakers regarding their presentations. In the following interview Srinivasan Shanmugam, Executive Director, Pharmaceutical Sciences, Business Support, and New Technologies at Adare Pharma Solutions discusses his breakfast session. 

Adare’s Optimµm® technology offers a unique and efficient method of fabricating monodisperse microparticles at reduced development time. The study herein uses Adare technology to fabricate monodisperse quetiapine microparticles to investigate the effects of formulation and size on the release profile of the API.

Throughout CPHI North America 2023, several Breakfast Sessions were held to start the day off right with a complimentary breakfast and a networking and learning session for our attendees. With insightful presentations from industry experts and partners, the CPHI North America Breakfast Sessions had something for everyone looking to fill their brains and their stomachs. 

In pharma, it is essential to identify the right partner to ensure a successful outcome. Time and time again, mistakes have been made in this process, causing clinical studies to fail and for the company to take a heavy hit. Want to avoid this? join our one-hour masterclass where we will devise a checklist for choosing your first CDMO. Discussion Points Thinking ahead before executing – why it is essential to map out what you need to achieve in all departments Why creating a business partnership case to potential CDMOs will determine if they are the right fit for you A checklist of the common pitfalls and how to avoid

Follow along for live updates from the Content team as we bring you the latest from CPHI North America 2023 - from session talks, panel discussions, interviews, and more, there's a lot to discover with CPHI Online at the Pennsylvania Convention Center! 

The following session has been SOLD OUT. For any inquiries, please contact a member of staff on the day Kickstart your CPHI North America with a coffee and pastry, connect with your peers, and listen to exclusive content surrounding patient-centric development The challenge of ensuring medication acceptance and adherence is particularly acute in special populations, such as pediatric and geriatric groups. These populations exhibit distinct pharmacokinetic and pharmacodynamic profiles due to their unique age-related physiological and biopharmaceutical characteristics. Consequently, the standard approaches to medication formulation often fall short of addressing their specific needs. This presentation will explore the unique aspects of pediatric and geriatric populations, highlighting the limitations encountered in the design and development of dosage forms tailored for them, and how those challenges are overcome. A significant focus will be placed on the strategies that can be employed to overcome these challenges, with an emphasis on Adare’s platform technologies. Through this discussion, we aim to shed light on the critical factors that must be considered in the development of effective, patient-friendly pharmaceutical formulations for pediatric and geriatric patients.